• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 16
  • 1
  • 1
  • 1
  • Tagged with
  • 23
  • 23
  • 23
  • 10
  • 8
  • 7
  • 5
  • 5
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 3
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
11

DESIGNS FOR TESTING LACK OF FIT FOR A CLASS OF SIGMOID CURVE MODELS

Su, Ying January 2012 (has links)
Sigmoid curves have found broad applicability in biological sciences and biopharmaceutical research during the last decades. A well planned experiment design is essential to accurately estimate the parameters of the model. In contrast to a large literature and extensive results on optimal designs for linear models, research on the design for nonlinear, including sigmoid curve, models has not kept pace. Furthermore, most of the work in the optimal design literature for nonlinear models concerns the characterization of minimally supported designs. These minimal, optimal designs are frequently criticized for their inability to check goodness of fit, as there are no additional degrees of freedom for the testing. This design issue can be a serious problem, since checking the model adequacy is of particular importance when the model is selected without complete certainty. To assess for lack of fit, we must add at least one extra distinct design point to the experiment. The goal of this dissertation is to identify optimal or highly efficient designs capable of checking the fit for sigmoid curve models. In this dissertation, we consider some commonly used sigmoid curves, including logistic, probit and Gompertz models with two, three, or four parameters. We use D-optimality as our design criterion. We first consider adding one extra point to the design, and consider five alternative designs and discuss their suitability to test for lack of fit. Then we extend the results to include one more additional point to better understand the compromise among the need of detecting lack of fit, maintaining high efficiency and the practical convenience for the practitioners. We then focus on the two-parameter Gompertz model, which is widely used in fitting growth curves yet less studied in literature, and explore three-point designs for testing lack of fit under various error variance structures. One reason that nonlinear design problems are so challenging is that, with nonlinear models, information matrices and optimal designs depend on the unknown model parameters. We propose a strategy to bypass the obstacle of parameter dependence for the theoretical derivation. This dissertation also successfully characterizes many commonly studied sigmoid curves in a generalized way by imposing unified parameterization conditions, which can be generalized and applied in the studies of other sigmoid curves. We also discuss Gompertz model with different error structures in finding an extra point for testing lack of fit. / Statistics
12

Bayesian D-Optimal Design for Generalized Linear Models

Zhang, Ying 12 January 2007 (has links)
Bayesian optimal designs have received increasing attention in recent years, especially in biomedical and clinical trials. Bayesian design procedures can utilize the available prior information of the unknown parameters so that a better design can be achieved. However, a difficulty in dealing with the Bayesian design is the lack of efficient computational methods. In this research, a hybrid computational method, which consists of the combination of a rough global optima search and a more precise local optima search, is proposed to efficiently search for the Bayesian D-optimal designs for multi-variable generalized linear models. Particularly, Poisson regression models and logistic regression models are investigated. Designs are examined for a range of prior distributions and the equivalence theorem is used to verify the design optimality. Design efficiency for various models are examined and compared with non-Bayesian designs. Bayesian D-optimal designs are found to be more efficient and robust than non-Bayesian D-optimal designs. Furthermore, the idea of the Bayesian sequential design is introduced and the Bayesian two-stage D-optimal design approach is developed for generalized linear models. With the incorporation of the first stage data information into the second stage, the two-stage design procedure can improve the design efficiency and produce more accurate and robust designs. The Bayesian two-stage D-optimal designs for Poisson and logistic regression models are evaluated based on simulation studies. The Bayesian two-stage optimal design approach is superior to the one-stage approach in terms of a design efficiency criterion. / Ph. D.
13

Model-Informed Medical Technology Development : A simulation study to evaluate the impact of model-based clinical study design and analysis on effect size estimates / Modellinformerad medicinteknisk utveckling : En simuleringsstudie för att utvärdera hur modellbaserad design och analys av kliniska studier påverkar uppskattningar av effektstorlek

Carvalho Lima Vieira Araujo, Manuel Maria January 2024 (has links)
Randomised controlled trials (RCT) are considered the gold standard for assessing the efficacy and safety of medical interventions. However, RCTs face unique challenges when applied to medical technologies, such as issues related to timing of assessment, eligible population, acceptability, blinding, choice of comparator group, and consideration for learning curves. To address these challenges, this thesis explores the adaptation of the model-informed drug development (MIDD) approach to the field of medical technology, using a case study on transurethral microwave thermotherapy (TUMT). The research employs non-linear mixed- effects (NLME) modelling and D-optimal design to optimise study designs and improve the reliability and efficiency of clinical trials. The impact of different sampling times, sample sizes, and learning curves on effect size estimates is analysed. The results show that optimising sampling points and sizes significantly improves the precision and reliability of effect size estimates and describes how MIDD can be a useful tool for this purpose. The study also highlights the limitations of the TUMT study design, suggesting ways in which the model-based approach could offer more robust and reliable clinical evidence generation. This research highlights the potential of the MIDD approach to streamline the medical technology clinical development process, enhance the quality of evidence, and address its inherent complexities. Future work should expand on these findings by exploring more complex error models and additional study designs and its related aspects. / Randomiserade kontrollerade studier (RCT) anses vara standard för att bedöma effekt och säkerhet i kliniska interventionsstudier. RCT:er står dock inför unika utmaningar när de tillämpas på medicinteknik såsom utmaningar relaterade till tidpunkt för bedömning, rekrytering av lämpliga studiedeltagare, acceptans, blindning, val av jämförelsegrupp och hänsyn till inlärningskurvor. För att hantera dessa utmaningar undersöker denna avhandling anpassningen av modellinformerad läkemedelsutveckling (MIDD) till området medicinteknik, med hjälp av en fallstudie om transuretral mikrovågstermoterapi (TUMT). I arbetet tillämpas icke-linjär, hierarkisk (NLME) modellering och D-optimal design för att optimera studiedesigner och förbättra tillförlitligheten i kliniska prövningar. Effekten av olika observationstider, antal studiedeltagare och inlärningskurvor på estimeringen av effektstorlek analyseras. Resultaten visar att optimering av observationstidpunkter och studiestorlek avsevärt förbättrar precisionen och tillförlitligheten av den estimerade effektstorleken och visar på hur MIDD kan vara ett användbart verktyg för detta ändamål inom medicinteknisk utveckling. Studien belyser också begränsningarna i studiedesignen för fallstudien och föreslår hur en modellbaserad metod skulle kunna erbjuda mer robust och tillförlitlig generering av klinisk evidens. Denna forskning belyser potentialen hos MIDD-metoder för att effektivisera den medicintekniska kliniska utvecklingsprocessen, förbättra kvaliteten av evidens, och hantera dess inneboende komplexitet. Framtida arbete bör utvidga dessa resultat genom att utforska mer komplexa modeller, ytterligare studiedesigner, och relaterade aspekter.
14

D-optimal designs for weighted polynomial regression - a functional-algebraic approach

Chang, Sen-Fang 20 June 2004 (has links)
This paper is concerned with the problem of computing theapproximate D-optimal design for polynomial regression with weight function w(x)>0 on the design interval I=[m_0-a,m_0+a]. It is shown that if w'(x)/w(x) is a rational function on I and a is close to zero, then the problem of constructing D-optimal designs can be transformed into a differential equation problem leading us to a certain matrix including a finite number of auxiliary unknown constants, which can be approximated by a Taylor expansion. We provide a recursive algorithm to compute Taylor expansion of these constants. Moreover, the D-optimal interior support points are the zeros of a polynomial which has coefficients that can be computed from a linear system.
15

Amélioration de la fiabilité d'un système complexe - Application ferroviaire : accès voyageurs

Turgis, Fabien 08 February 2013 (has links)
Les grandes entreprises ferroviaires intègrent au niveau du matériel roulant une grande variété de systèmes complexes qui se doivent d’être fiables et ce, dès le démarrage du service commercial. Ce travail de thèse propose une méthodologie expérimentale pour l’amélioration de la robustesse d’un système prédominant, à savoir l’accès voyageurs. L'objectif est d'améliorer sa fiabilité intrinsèque dans un laps de temps raisonnable dans le cadre de projet industriel contraint par le temps. La méthodologie expérimentale proposée s’appuie sur la méthode des essais aggravés et accélérés de fiabilité, et se veut être optimisée grâce à l’utilisation de plans d’expériences D-optimaux. Après une analyse bibliographique, suivie d’une étude sur l’utilisation des plans d’expériences D-optimaux, ce travail expose les méthodes et moyens expérimentaux mis en place pour utiliser les plans d’expériences dans un contexte industriel. La dernière partie de cette thèse contient les résultats quantitatifs et qualitatifs issus des expérimentations réaliséessur le banc d'essais du système accès voyageurs développé par Bombardier. / The train manufacturer companies handle a large number of complex systems in their trains. These systems must be reliable to ensure reliability of the final product as soon the entry into commercial services. This thesis provides an experimental solution to improve robustness of a predominate system, namely passengers access system. The goal is to improve inherent reliability in a reasonable amount of time to be integrated in a project phase. This experimental method is based on testing aggravated and accelerated method temporally optimized with using of D-optimal design of experiment. After a literature review, followed by a focus on the definition and use of experimental design D-optimal, this work will present experimental methods and means used to set up the experimental design in an industrial context. The last part of this thesis contains quantitative and qualitative results performed on the passenger’s access test bench developed by Bombardier.
16

Experimental Designs at the Crossroads of Drug Discovery

Olsson, Ing-Marie January 2006 (has links)
<p>New techniques and approaches for organic synthesis, purification and biological testing are enabling pharmaceutical industries to produce and test increasing numbers of compounds every year. Surprisingly, this has not led to more new drugs reaching the market, prompting two questions – why is there not a better correlation between their efforts and output, and can it be improved? One possible way to make the drug discovery process more efficient is to ensure, at an early stage, that the tested compounds are diverse, representative and of high quality. In addition the biological evaluation systems have to be relevant and reliable. The diversity of the tested compounds could be ensured and the reliability of the biological assays improved by using Design Of Experiments (DOE) more frequently and effectively. However, DOE currently offers insufficient options for these purposes, so there is a need for new, tailor-made DOE strategies. The aim of the work underlying this thesis was to develop and evaluate DOE approaches for diverse compound selection and efficient assay optimisation. This resulted in the publication of two new DOE strategies; D-optimal Onion Design (DOOD) and Rectangular Experimental Designs for Multi-Unit Platforms (RED-MUP), both of which are extensions to established experimental designs.</p><p>D-Optimal Onion Design (DOOD) is an extension to D-optimal design. The set of possible objects that could be selected is divided into layers and D-optimal selection is applied to each layer. DOOD enables model-based, but not model-dependent, selections in discrete spaces to be made, since the selections are not only based on the D-optimality criterion, but are also biased by the experimenter’s prior knowledge and specific needs. Hence, DOOD selections provide controlled diversity.</p><p>Assay development and optimisation can be a major bottleneck restricting the progress of a project. Although DOE is a recognised tool for optimising experimental systems, there has been widespread unwillingness to use it for assay optimisation, mostly because of the difficulties involved in performing experiments according to designs in 96-, 384- and 1536- well formats. The RED-MUP framework combines classical experimental designs orthogonally onto rectangular experimental platforms, which facilitates the execution of DOE on these platforms and hence provides an efficient tool for assay optimisation.</p><p>In combination, these two strategies can help uncovering the crossroads between biology and chemistry in drug discovery as well as lead to higher information content in the data received from biological evaluations, providing essential information for well-grounded decisions as to the future of the project. These two strategies can also help researchers identify the best routes to take at the crossroads linking biological and chemical elements of drug discovery programs.</p>
17

A characterization of weight function for construction of minimally-supported D-optimal designs for polynomial regression via differential equation

Chang, Hsiu-ching 13 July 2006 (has links)
In this paper we investigate (d + 1)-point D-optimal designs for d-th degree polynomial regression with weight function w(x) > 0 on the interval [a, b]. Suppose that w'(x)/w(x) is a rational function and the information of whether the optimal support contains the boundary points a and b is available. Then the problem of constructing (d + 1)-point D-optimal designs can be transformed into a differential equation problem leading us to a certain matrix with k auxiliary unknown constants. We characterize the weight functions corresponding to the cases when k= 0 and k= 1. Then, we can solve (d + 1)-point D-optimal designs directly from differential equation (k = 0) or via eigenvalue problems (k = 1). The numerical results show us an interesting relationship between optimal designs and ordered eigenvalues.
18

An Arcsin Limit Theorem of Minimally-Supported D-Optimal Designs for Weighted Polynomial Regression

Lin, Yung-chia 23 June 2008 (has links)
Consider the minimally-supported D-optimal designs for dth degree polynomial regression with bounded and positive weight function on a compact interval. We show that the optimal design converges weakly to the arcsin distribution as d goes to infinity. Comparisons of the optimal design with the arcsin distribution and D-optimal arcsin support design by D-efficiencies are also given. We also show that if the design interval is [−1, 1], then the minimally-supported D-optimal design converges to the D-optimal arcsin support design with the specific weight function 1/¡Ô(£\-x^2), £\>1, as £\¡÷1+.
19

An Arcsin Limit Theorem of D-Optimal Designs for Weighted Polynomial Regression

Tsai, Jhong-Shin 10 June 2009 (has links)
Consider the D-optimal designs for the dth-degree polynomial regression model with a bounded and positive weight function on a compact interval. As the degree of the model goes to infinity, we show that the D-optimal design converges weakly to the arcsin distribution. If the weight function is equal to 1, we derive the formulae of the values of the D-criterion for five classes of designs including (i) uniform density design; (ii) arcsin density design; (iii) J_{1/2,1/2} density design; (iv) arcsin support design and (v) uniform support design. The comparison of D-efficiencies among these designs are investigated; besides, the asymptotic expansions and limits of their D-efficiencies are also given. It shows that the D-efficiency of the arcsin support design is the highest among the first four designs.
20

Experimental Designs at the Crossroads of Drug Discovery

Olsson, Ing-Marie January 2006 (has links)
New techniques and approaches for organic synthesis, purification and biological testing are enabling pharmaceutical industries to produce and test increasing numbers of compounds every year. Surprisingly, this has not led to more new drugs reaching the market, prompting two questions – why is there not a better correlation between their efforts and output, and can it be improved? One possible way to make the drug discovery process more efficient is to ensure, at an early stage, that the tested compounds are diverse, representative and of high quality. In addition the biological evaluation systems have to be relevant and reliable. The diversity of the tested compounds could be ensured and the reliability of the biological assays improved by using Design Of Experiments (DOE) more frequently and effectively. However, DOE currently offers insufficient options for these purposes, so there is a need for new, tailor-made DOE strategies. The aim of the work underlying this thesis was to develop and evaluate DOE approaches for diverse compound selection and efficient assay optimisation. This resulted in the publication of two new DOE strategies; D-optimal Onion Design (DOOD) and Rectangular Experimental Designs for Multi-Unit Platforms (RED-MUP), both of which are extensions to established experimental designs. D-Optimal Onion Design (DOOD) is an extension to D-optimal design. The set of possible objects that could be selected is divided into layers and D-optimal selection is applied to each layer. DOOD enables model-based, but not model-dependent, selections in discrete spaces to be made, since the selections are not only based on the D-optimality criterion, but are also biased by the experimenter’s prior knowledge and specific needs. Hence, DOOD selections provide controlled diversity. Assay development and optimisation can be a major bottleneck restricting the progress of a project. Although DOE is a recognised tool for optimising experimental systems, there has been widespread unwillingness to use it for assay optimisation, mostly because of the difficulties involved in performing experiments according to designs in 96-, 384- and 1536- well formats. The RED-MUP framework combines classical experimental designs orthogonally onto rectangular experimental platforms, which facilitates the execution of DOE on these platforms and hence provides an efficient tool for assay optimisation. In combination, these two strategies can help uncovering the crossroads between biology and chemistry in drug discovery as well as lead to higher information content in the data received from biological evaluations, providing essential information for well-grounded decisions as to the future of the project. These two strategies can also help researchers identify the best routes to take at the crossroads linking biological and chemical elements of drug discovery programs.

Page generated in 0.0489 seconds